Stockreport

ContraFect Presents Additional Positive Data from the Phase 2 Trial of Exebacase at the 29th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)

ContraFect Corporation  (CFRX) 
Last contrafect corporation earnings: 3/18 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: ir.contrafect.com
PDF New data include secondary endpoint analyses of clinical responder rates at Day 7, End of Treatment, and Test of Cure, and pre-specified analyses of the clinical respond [Read more]